Plasticell
Plasticell is a UK-based biotech founded in 2002 developing allogeneic natural killer (NK) cell therapies and hematopoietic stem cell therapies, focused on industrial-scale manufacturing of cell-based cancer immunotherapies. It operates pre-commercially, funded by equity rounds and Innovate UK grants.
- Company typePrivate
- Founded2002
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Plasticell does
Plasticell is a privately held UK biotechnology company founded in 2002 and headquartered in London, with 11–50 employees. Originally established to provide cell-based screening technology for the discovery of small-molecule drugs that regenerate cells of the body, the company has shifted its strategic emphasis toward cell and gene therapy manufacturing. Its current portfolio centers on allogeneic natural killer (NK) cell-based immunotherapies for cancer treatment, alongside hematopoietic stem cell therapies and broader allogeneic immunotherapy programs.
The company's core technology is a manufacturing platform designed to produce allogeneic NK cell therapies at industrial scale, developed in collaboration with Cell and Gene Therapy Catapult and Imperial College London under an £800,000 Innovate UK grant awarded in August 2023. The platform targets cost-effective, scalable production of off-the-shelf cell therapies as an alternative to autologous approaches. Plasticell has also historically developed hematopoietic stem cell therapies, supported by a £1.4 million equity financing round in May 2021.
Plasticell operates a pre-commercial R&D business model. No products have reached market, no pricing is disclosed, and revenue is not reported in available sources. The company funds operations through periodic equity financings and non-dilutive government grants, with cumulative disclosed funding of approximately $17 million across seven rounds since 2007, including equity rounds, venture investment (The Capital Fund, 2007), and multiple Innovate UK grants. End customers, where identifiable, would be oncology treatment providers, but no commercial agreements or named accounts are disclosed. The company is led by founder and chairman Yen Choo.
Plasticell firmographics
Firmographics- Name
- Plasticell
- Legal name
- Plasticell
- Website
- https://plasticell.co.uk
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Plasticell is a UK-based biotech founded in 2002 developing allogeneic natural killer (NK) cell therapies and hematopoietic stem cell therapies, focused on industrial-scale manufacturing of cell-based cancer immunotherapies. It operates pre-commercially, funded by equity rounds and Innovate UK grants.
- Ownership category
- akta.pro rank
Where Plasticell is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Plasticell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Plasticell product offering
Product offeringCore offering
Plasticell is a cell and gene therapy company that develops allogeneic (off-the-shelf) cell immunotherapies, primarily natural killer (NK) cell therapies for cancer treatment and hematopoietic stem cell therapies. Its central focus is an industrial-scale manufacturing platform, developed in partnership with Cell and Gene Therapy Catapult and Imperial College London, designed to produce allogeneic cell immunotherapies at scale so that cancer cell therapies become more cost-effective and broadly accessible.
Product overview
Plasticell is a cell and gene therapy research company developing multiple therapeutic platforms. The company operates a manufacturing platform for allogeneic cell immunotherapies (developed with Cell and Gene Therapy Catapult and Imperial College London under Innovate UK funding), focused on producing allogeneic natural killer (NK) cell therapies at industrial scale. The product portfolio includes NK cell-based cancer immunotherapies, hematopoietic stem cell therapies, and broader allogeneic immunotherapy programs—all aimed at making cell-based cancer treatments more cost-effective and accessible.
Differentiator
Problem solved
Functional benefit
Products and services
- Manufacturing Platform for Allogeneic Cell Immunotherapies A manufacturing platform co-developed with Cell and Gene Therapy Catapult and Imperial College London, funded by Innovate UK, designed to produce allogeneic natural killer (NK) cell therapies at industrial scale for cost-effective and accessible cancer treatments.
- Allogeneic NK Cell Therapy Pipeline Natural killer (NK) cell-based immunotherapies for cancer treatment, developed through the Innovate UK-funded manufacturing platform to enable industrial-scale production of off-the-shelf cancer therapies.
- Hematopoietic Stem Cell Therapies Stem cell-based therapies targeting hematopoietic (blood-forming) cells, supported by the company's equity financing rounds for cell and gene therapy research.
- Allogeneic Immunotherapies Off-the-shelf allogeneic cell immunotherapies derived from donor cells, designed to be more accessible and cost-effective than autologous approaches for cancer treatment.
Quantifiable outcome
- Production of allogeneic NK cell therapies at industrial scale for more cost-effective and accessible cancer treatments
Companies that use Plasticell
Customer profileSegments1 record
Ideal customer profiles1 record
Plasticell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Plasticell partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Cell and Gene Therapy CatapultcoreCollaborative partnership to develop a manufacturing platform for allogeneic cell immunotherapies. Cell and Gene Therapy Catapult brings manufacturing expertise and infrastructure to advance NK cell therapy production at industrial scale. This is a core strategic partnership focused on advancing cell therapy manufacturing capabilities.
- Imperial College LondoncoreAcademic partnership contributing research expertise to the development of a manufacturing platform for allogeneic cell immunotherapies. Imperial College London provides scientific research capabilities for advancing NK cell therapy development at industrial scale.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Plasticell competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights5 records
Customer concentration
Plasticell social profiles
Digital presencePlasticell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Plasticell leadership team
Management profileNumber of profiles
Profiles1 record
Plasticell funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Plasticell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Plasticell
What does Plasticell do?
Plasticell is a cell and gene therapy company that develops allogeneic (off-the-shelf) cell immunotherapies, primarily natural killer (NK) cell therapies for cancer treatment and hematopoietic stem cell therapies. Its central focus is an industrial-scale manufacturing platform, developed in partnership with Cell and Gene Therapy Catapult and Imperial College London, designed to produce allogeneic cell immunotherapies at scale so that cancer cell therapies become more cost-effective and broadly accessible.
Is Plasticell a public or private company?
Plasticell is a private company. It is classified as venture growth investor backed and is currently operating.
When was Plasticell founded?
Plasticell was founded in 2002. It employs 11 to 50 people.
Where is Plasticell based?
Plasticell is headquartered in London, United Kingdom, in the Europe region.
Does Plasticell have an API?
No public API is recorded for Plasticell.